Navigation Links
Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders

MENLO PARK, Calif. and INGELHEIM, Germany, Dec. 18, 2013 /PRNewswire/ -- Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration agreement for the discovery of new ways of treating psychiatric disorders.  Circuit Therapeutics provides an innovative platform that allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors.  Circuit Therapeutics' key technology, optogenetics, allows the control of individual nerve cells and circuits within the brain enabling their functional identification and characterization.  The combination of optogenetics and sophisticated molecular technologies provides an unprecedented level of focus to identify novel drug targets and approaches for drug development. The new insights enabled by circuit-based analysis provide fundamentally differentiated approaches to understanding and treating brain disorders, which have otherwise been difficult to address.


Under the terms of the agreement the research and development capabilities of the two companies will be brought together to provide novel avenues for drug discovery in a three-year research program.  Further details of the agreement are not disclosed.

"We are excited to work with Boehringer Ingelheim to utilize Circuit's unique capabilities to advance drug discovery. The innovative and ambitious vision and passion of Boehringer Ingelheim to make a difference in the area of neuropsychiatric disease treatments combined with Circuit's innovative technologies makes an ideal partnership. We look forward to a highly productive research collaboration that will provide transformational drugs to impact patients' lives," said Fred Moll, Chairman of Circuit Therapeutics.

"We are very enthusiastic about being able to work in a partnership with Circuit Therapeutics, one of the leading organizations in the field of circuit biology and optogenetics," said Dr. Bernd Sommer, the head of neuroscience research at Boehringer Ingelheim.  "We believe that, by working together to investigate maladaptive brain circuitry with this exciting approach, we will be able to obtain a better understanding of the neurobiological basis of human neuropsychiatric disorders, thereby allowing us to make a difference to science, disease and patients."

About Circuit Therapeutics
Circuit Therapeutics is a privately held discovery stage biotechnology company based in Menlo Park, California. The company's cutting edge technologies focused on neural circuits are being applied to enable new ways of drug discovery and development of direct therapeutic interventions across a broad range of indications.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.

For more information please visit

Boehringer Ingelheim
Dr. Reinhard Malin
Director Corporate Communications
Tel.: +49 (6132) 77-90815

Boehringer Ingelheim US (for US media enquiries)
Sperry Mylott
Senior Associate Director, U.S. Corporate Communications
Tel.: (203) 798-4630

Circuit Therapeutics
Dr. Karoly Nikolich
President and Founder
1505 O'Brien Drive
Menlo Park, California 94025
Tel.: (650) 543-1401

SOURCE Circuit Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omnetics Ruggedized Strip Connectors Provide Fast and Firm Mating for High Density Circuits in Miniature and Portable Electronics
2. Women Injured by Bestselling Diabetes Drug Lipitor Take on Pfizer in St. Louis Circuit Court
3. Human Circuit Recognized as Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2013
4. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
5. Human Circuit Recognized as an Industry Leader in Commercial Integrator Magazines Business Series as a Top 5 Healthcare Market Media Integrator for 2012
6. Analog Integrated Circuits (IC) Market to 2016 - Electric Vehicles and Portable Medical Equipment Segments to be Main Source of Future Growth
7. Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
8. Halozyme Therapeutics Announces Executive Transitions
9. Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
10. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
11. Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA)
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... WOODBURY, N.Y. , Nov. 25, 2015  Linden ... access and optimizing treatment outcomes for patients suffering from ... its request for a Temporary Restraining Order (TRO) enjoining ... between the two companies. --> ... aggressively pursuing all of its legal options. ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind ... mental health and wellness consultation, has collaborated with a leading web-based marketplace for ... gap experienced by parents and bring advice from parenting experts within their reach. ...
(Date:11/27/2015)... ... , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search ... one of Joplin's most famous and beautiful concert posters. The concert was held on ... Arbor. The According to Hawley, "It is hard to believe that Joplin's stardom was ...
Breaking Medicine News(10 mins):